Worldwide Prevalence of *mcr*-mediated Colistin-Resistance *Escherichia coli* in Isolates of Clinical Samples, Healthy Humans, and Livestock—A Systematic Review and Meta-Analysis

Carlos Bastidas-Caldes¹, ₂, **, Jacobus H. de Waard ³, Maria Soledad Salgado ¹, María José Villacís ¹, Marco Coral-Almeida ³, ⁴, Yoshimasa Yamamoto ⁴ and Manuel Calvopiña ³

Abstract: Background: Antimicrobial resistance is a serious public-health problem throughout the world. *Escherichia coli*, the most common Gram-negative microorganism, has developed different resistance mechanisms, making treating infections difficult. Colistin is considered a last-resort drug in the treatment of infections caused by *E. coli*. Plasmid-mediated mobile-colistin-resistant (*mcr*) genes in *E. coli*, now disseminated globally, are considered a major public-health threat. Humans, chickens, and pigs are the main reservoirs for *E. coli* and the sources of antibiotic resistance. Hence, an up-to-date and precise estimate of the global prevalence of *mcr* resistance genes in these reservoirs is necessary to understand more precisely the worldwide spread and to more effectively implement control and prevention strategies. **Methodology:** Publications were identified in the PubMed database on the basis of the PRISMA guidelines. English full-text articles were selected from December 2014 to March 2021. Descriptive statistics and a meta-analysis were performed in Excel and R software, respectively. Colistin resistance was defined as the molecular-genetic detection of the *mcr* genes. The crude and estimated prevalence were calculated for each host and continent. The studies were divided into two groups: community-based when they involved isolates from healthy humans, chickens, or pigs, and clinical studies when they involved only hospital, outpatient, or laboratory isolates. **Results:** A total of 1278 studies were identified and 218 were included in this systematic review and meta-analysis, divided into community studies (159 studies) and clinical studies (59 studies). The general prevalence of *mcr*-mediated colistin-resistant *E. coli* (*mcrMCRE*) was 6.51% (n = 11,583/177,720), reported in 54 countries and on five continents; Asia with 119 studies followed by Europe with 61 studies registered the most articles. Asia reported the major diversity of *mcr* genes was demonstrated on different continents of the world facilitates tracing the occurrence of *E. coli* isolates from the selected reservoirs. Asia with 119 studies followed by Europe with 61 studies registered the most articles. Asia reported the major diversity of *mcr* variants (eight of nine, except *mcr*-2). Worldwide, chickens and pigs proved to be the principal reservoir of *mcr* with an estimated prevalence of 15.8% and 14.9%, respectively. Healthy humans and clinical isolates showed a lower prevalence with 7.4% and 4.2% respectively. **Conclusions:** In this systematic review and meta-analysis, the worldwide prevalence of *mcr* in *E. coli* isolated from healthy humans, chickens, and pigs was investigated. A wide prevalence and distribution of *mcr* genes was demonstrated on all continents in *E. coli* isolates from the selected reservoirs. Understanding the epidemiology and occurrence in the reservoirs of *mcr* in *E. coli* on different continents of the world facilitates tracing how *mcr* genes are transmitted and determining the infection risks for humans. This knowledge can be used to reduce the incidence of zoonotic transmission by implementing the appropriate control programs.
Keywords: colistin; resistance; mcr; Escherichia coli; clinical; community; animals

1. Introduction

The emergence of antibiotic-resistant bacteria is one of the most urgent human and veterinary health problems worldwide, representing a major threat to food security [1–3]. Serious infections caused by bacteria exhibiting multiple resistances to most commercially available antibiotics such as fluoroquinolones, aminoglycosides, carbapenem, and β-lactams have been increasing in recent years. The lack of development of new antimicrobial agents has led to the reevaluation of colistin [4–6] with the drug now regaining clinical value as a last-resort pharmacon in the treatment of infections caused by Gram-negative bacteria [7,8]. Over the last few years, colistin was used excessively in veterinary medicine as a prophylactic treatment and as a livestock-growth promoter, resulting in the consequent appearance of new resistance mechanisms in bacteria [9,10].

*Escherichia coli* is a bacterium commonly found in the gut of humans and warm-blooded animals. Most strains of *E. coli* are harmless. Certain strains, however, can cause severe foodborne disease. For example, a systematic review revealed a substantial burden of *E. coli* bacteremia in high income countries, with an estimated incidence of 48 cases per 100,000 person-years [11]. With respect to antibiotic susceptibility, a study in the USA with 67,583 patients with invasive *E. coli* infections found that 9.18% were resistant to extended-spectrum cephalosporins, 28.2% to fluoroquinolones, and 0.14% to carbapenems. Resistance to extended-spectrum cephalosporins increased from 5.46% to 13.0% during the 8-year study period [12].

The transmission of *E. coli* between animals and humans is primarily through the consumption of contaminated food such as raw or undercooked ground meat products and raw milk or the contamination of water with animal feces. Contaminated surfaces and kitchen utensils can also lead to infection. This microorganism furthermore has a great capacity to accumulate antibiotic-resistance mechanisms mainly through horizontal gene transfer [13]. Among the acquired mechanisms are the genes that encode carbapenemases, β-lactamases, methylases, and quinolone resistance; while in recent years the mobile-colistin-resistance (*mcr*) gene responsible for insensitivity to that antibiotic has become prevalent. Mobile genetic elements—such as transposons, multiple resistance plasmids, and gene cassettes in integrons—play a key role in the dissemination of these resistance genes, causing treatment failure in human and veterinary medicine [14–16].

With respect to colistin resistance, chromosomal resistance was initially the principal mechanism, where structural modifications of the bacterial lipopolysaccharide were the reason for that resistance in Gram-negative bacteria. Several systems like PhoPQ and PmrAB or mgrB exhibited phenotypic changes caused by mutations. As a result, the effective binding between the lipopolysaccharide present in the bacterial membrane and colistin was prevented [17]. In 2015, however, a new resistance mechanism was described; the *mcr* gene. This gene encodes a transferase enzyme that catalyzes a modification of the lipid-A lipopolysaccharide of the bacterium [18]. Being a transposable genetic element, *mcr* was found within different bacterial plasmids such as the IncX4 and IncHI2, hence facilitating a horizontal gene transfer [14]. Since that time, studies of Enterobacteria harboring *mcr* genes have been reported worldwide and to date variants ranging from *mcr-1* to *mcr-10* have been described [18–26]. Bacteria that carry these genes have been isolated from poultry, pigs, cattle, and food products derived from those animals, but also in human clinical isolates. Notwithstanding, few studies have carried out an in-depth, comprehensive analysis within the one-health context, i.e., one linking the health of humans closely connected to that of the animals within the same shared environment [27–29].

Currently, little is still known about the impact of the rapid spread of the *mcr* over the entire world’s continents. The World Health Organization recommends an enhancement in the detection and epidemiologic surveillance of microorganisms possessing this resistance,
with one of the control strategies being the disclosure of worldwide information concerning colistin resistance in order to alert healthcare workers and decision-making entities [30–33]. Therefore, the present systematic review and meta-analysis aims at compiling the available information about mcr in E. coli and estimating the prevalence in three of the main hosts (pigs, chickens, and humans) along with the gene’s distribution over the different continents of the world.

2. Results

2.1. Studies Selection

From an initial number of 1278 articles, 218 studies were included for quantitative synthesis. Of the studies, 72.9% (n = 159/218) corresponded to community studies that involved healthy humans, chickens and/or pigs. The other 27.1% (n = 59/218) corresponded to clinical studies where the samples were obtained from patients with an infectious disease (Figure 1) (Supplementary Material Tables S1–S4).

Figure 1. PRISMA flow diagram of the review process; selection and inclusion of studies for community and clinical data. Flow diagram for the review process involving the selection and inclusion of studies for community and clinical data from Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
2.2. Global Spread of mcr in Escherichia coli

Five continents reported data, with the 218 publications accounting for a total of 54 countries that reported mcrMCRE. The 119 studies on the continent of Asia were distributed over 19 countries, followed by Europe with 61 studies distributed over 16 countries, Africa with 20 studies in nine countries, the Americas (North, Central, and South) with 17 studies in nine countries, and Oceania with one study in Australia (Figure 2).

We found China to be the country with the most frequently reported incidence of mcr with 54 studies—followed by Spain with 13 studies; Italy with 12; South Korea and Vietnam with 10; Japan with eight; Germany with seven; Nepal with six; Brazil, Pakistan, Taiwan, United Kingdom, Egypt, and Portugal with five; France, India, Bangladesh, and Tunisia with four; Argentina, Belgium, Sweden, Switzerland, Thailand, and South Africa with three; and the United States, Cambodia, Lebanon, Nigeria, Poland, Tanzania, Algeria, Canada, and Qatar with two. Finally, several countries reported a single study such as Australia, Bolivia, Denmark, Ecuador, Ireland, Romania, Senegal, Venezuela, Myanmar, Colombia, Hungary, Greece, Israel, Oman, Morocco, Philippines, Malaysia, Netherlands, Turkey, Uruguay, Sao Tomé, and Prince. Figure 2 details the distribution between the clinical and community studies in each country.

In all the studies, nine variants of mcr genes were reported: mcr-1 through mcr-9. The distribution of the variants over the world map was highly diverse, with Asia exhibiting the greatest diversity in the prevalence of all nine. On the European continent, the variants mcr-1 through mcr-5 were reported, while the Americas documented only the mcr-1 and mcr-3. Finally, Africa registered the mcr-1, mcr-5, and mcr-8 variants, but Oceania only the mcr-1.

Figure 2. Global spread of mcr genes in E. coli. The countries colored from red-orange to yellow plus white represent the total number of studies for those countries according to the key to the lower left, while the countries in gray are without studies. The triangles in the black-to-white scale represent the number of studies with community samples (healthy humans, pigs, and/or chickens). The circles in the black-to-white scale represent the number of studies with clinical samples.

In all the studies, nine variants of mcr genes were reported: mcr-1 through mcr-9. The distribution of the variants over the world map was highly diverse, with Asia exhibiting the greatest diversity in the prevalence of all nine. On the European continent, the variants mcr-1 through mcr-5 were reported, while the Americas documented only the mcr-1 and mcr-3. Finally, Africa registered the mcr-1, mcr-5, and mcr-8 variants, but Oceania only the mcr-1.
The worldwide distribution of mcr in *E. coli* (Table 1) manifested a wide variation. The total crude prevalence was 6.52% (n = 11,583/177,720) at a prevalence of 8.71% (n = 15,001/172,140) in non-clinical isolates and one of 1.76% (n = 1020/58,033) in clinical isolates. Africa was the continent with the highest gross prevalence of *E. coli* antibiotic resistance mediated by mcr genes at 10.1% (n = 273/2715), followed closely by Asia at 9.24% (n = 8381/90,707). The Americas at 7.65% (n = 624/8161) and Europe at 3.03% (n = 2305/76,137) exhibited the lowest prevalence of mcr genes.

| Data Categories | (n) = mcr-E.coli/E. coli | Crude Prevalence | Estimated Prevalence |
|-----------------|--------------------------|------------------|----------------------|
| Host            |                          |                  |                      |
| Healthy Humans *| (789/23585)              | 3.35             | 7.4                  |
| Pigs *          | (7089/80600)             | 8.8              | 14.9                 |
| Chickens *      | (7134/68362)             | 10.44            | 15.8                 |
| Clinical        | (1020/58033)             | 1.76             | 4.2                  |
| Continent       |                          |                  |                      |
| Asia            | (8381/90707)             | 9.2              | 11.5                 |
| The Americas    | (624/8161)               | 7.6              | 21.7                 |
| Africa          | (273/2715)               | 10.08            | 16.7                 |
| Europe          | (2305/76137)             | 3.03             | 9.1                  |

* Healthy humans, pigs and chickens were considered as non-clinical samples.

The meta-analysis by continents indicated a heterogeneity among the studies. Asia with a total of 119 studies reported an estimated prevalence of 11.5% (8.9–14.7) at a 95% CI and an I² = 99% (Supplementary Material Figure S1) and Europe with 61 studies one of 9.1% (5.7–14.1) at a 95% CI and an I² = 99% (Supplementary Material Figure S2). The 20 studies in Africa registered a prevalence of 16.7% (8.3–30.9) at a 95% CI and an I² = 95% (Supplementary Material Figure S3), and finally, the 17 studies in the Americas indicated an estimated prevalence of 21.4% (7.7–46.9) at a 95% CI and an I² = 98% (Supplementary Material Figure S4).

2.3. The mcr in Healthy Humans, Chickens, and Pigs

Community studies evidenced a wide distribution of host and samples. The most commonly studied hosts worldwide were chickens with 94 studies with mcr in *E. coli* indicating a gross prevalence of 10.4% (n = 7134/68,362), followed by 85 studies on pigs at 8.80% (n = 7089/80,600) and 30 studies on healthy humans at 3.35% (n = 789/23,585). The samples of the studies originated from one, two, or three host sources, with 52 being carried out with samples from chickens, 48 from pigs, and 15 only from healthy humans. Other studies combined samples; with seven studies using samples from chickens and humans, two samples from pigs and humans, 29 samples from pigs and chickens, and six samples from all three hosts (humans, chickens, and pigs).

The hosts registered in the meta-analysis of community studies proved to be heterogeneous for mcr in *E. coli* isolates. The meta-analysis of the studies on chickens registered the highest estimated prevalence of 15.8% [11.7–20.9] at a 95% CI and an I² = 98% (Supplementary Material Figure S5), followed by those on pigs at an estimated prevalence of 14.9% (10.8–20.1) at a 95% CI and an I² = 99% (Supplementary Material Figure S6). Finally, healthy humans exhibited an estimated prevalence of 7.4% (3.9–13.6) at a 95% CI and an I² = 98% (Supplementary Material Figure S7). Table 1 summarizes the comparisons between the gross and estimated prevalence.

The *mcr-1* variant is predominant and widely distributed in all the continents and hosts. The studies documented that the diversity and abundance of the variants of mcr genes found in animals and healthy humans was greater in Asia, with eight variants (*mcr-1–mcr-3, mcr-5–mcr-9*), followed by Europe with five (*mcr-1–mcr-5*), Africa with three (*mcr-1, mcr-5, and mcr-8*), and finally the Americas with only two (*mcr-1 and mcr-3*). Pigs presented a greater diversity of mcr variants than the other hosts, reaching up to eight in Asia and five...
in Europe. Chickens and humans have one to three variants depending on their geographic location (Figure 3).

Figure 3. Global distribution of prevalence and diversity of \textit{mcr} variants of \textit{E. coli} isolates described in community studies of healthy humans, pigs, and chickens. The colored pie charts represent the percent distribution of \textit{mcr} variants in each continent—light green, Asia; red, Europe; yellow, Africa; dark green, the Americas. The small figure silhouettes indicate the hosts (healthy humans, pigs, or chickens).

2.4. \textit{mcr} in Clinical Samples

The 59 clinical studies comprising 58,033 samples of clinical or ambulatory origin manifested less diversity of \textit{mcr}-gene variants, with only four variants being observed worldwide (\textit{mcr}-1–\textit{mcr}-3, and \textit{mcr}-5). Because of the variability of the origin of the clinical samples, the latter were grouped into six categories: blood, feces, urine, respiratory, body fluids, and other samples (Supplementary Material Table S5). The continent that displayed the most diversity in their clinical studies was Asia with three variants (\textit{mcr}-1–\textit{mcr}-3), followed by Europe with two variants (\textit{mcr}-1 and \textit{mcr}-2), the Americas with an additional two variants (\textit{mcr}-1 and \textit{mcr}-5), and finally Africa with only one variant, the \textit{mcr}-1.

Despite the low diversity, the continent with the highest prevalence of the \textit{mcr} gene in clinical samples was Africa at 7.58\% (n = 53/699), where \textit{mcr}-1 was the only reported gene, followed by the Americas at 3.59\% (n = 436/12,128) distributed between the \textit{mcr}-1 and \textit{mcr}-5 variants, with Asia and Europe reporting the lowest respective prevalence of \textit{mcr} genes at 1.56\% (n = 745/47,611) and 0.522\% (n = 144/27,600). Figure 4 illustrates the distribution, frequency, and diversity of the variants in relation to the origin of the samples. Like the previous meta-analyses, those for the 59 clinical studies revealed a high heterogeneity with an estimated prevalence of 4.2\% (2.4–7.3) at a 95\% CI and an $I^2 = 98\%$ (Supplementary Material Figure S8).
Asia proved to be the continent with the most studies and countries that reported mcr. This practice is consistent with the high estimated prevalence in the meta-analysis for mcr in those respective domestic animals of 15.8% and 14.9% compared to the lowest estimated prevalence for healthy humans and clinical samples at 7.4% and 4.2%, respectively. The results of this review have enabled us to compare the estimates of the prevalence and global geographical distribution of mcr and its variants within the mcrMCRE in the different continents and the principal hosts. The present study revealed an increase in the dispersion of mcr with respect to the number of countries reporting cases and the diversity of variants over the findings from previous similar reviews covering just 31 [34] and 47 [1] countries. Asia proved to be the continent with the most studies and countries that reported mcr. Similarly, Europe and the Americas—in countries such as Spain, Italy, Germany, United States, Brazil, and Argentina—have reported an increase in mcr-mediated colistin resistance in pathogenic E. coli.

This rapid dissemination can be attributed to the ability of mcr genes to be dispersed by horizontal transfer via plasmids and transposons. Up to 11 types of plasmids capable of carrying mcr genes have been reported such as IncI2, IncHI2, and IncX4 [35], along with transposable elements such as ISApl1 [34]. We can assume that these genetic transmissions can be favored by the exposure to persistent antibiotic pressure at low concentrations of colistin or other polymyxins. That pressure, in turn, may be especially linked to veterinary medicine in treatments for infection or prophylaxis and/or the latter rationale in the frequent use of colistin-containing feed in chickens and pigs to prevent infection [9,36]. This practice is consistent with the high estimated prevalence in the meta-analysis for mcr in those respective domestic animals of 15.8% and 14.9% compared to the lowest estimated prevalence for healthy humans and clinical samples at 7.4% and 4.2%, respectively. The 

3. Discussion
3.1. Global Prevalence of mcr in the Hosts Studied

To the best of our knowledge, the present meta-analysis is the first systematic review of mcrMCRE that links the resistance to colistin in nonclinical and clinical samples of humans to two principal feed animals (pigs and chickens) in a one-health context as cited above. The results of this review have enabled us to compare the estimates of the prevalence and global geographical distribution of mcr and its variants within the mcrMCRE in the different continents and the principal hosts. The present study revealed an increase in the dispersion of mcr with respect to the number of countries reporting cases and the diversity of variants over the findings from previous similar reviews covering just 31 [34] and 47 [1] countries.
latter values being much lower does not, however, necessarily mean that resistance to colistin may be considered less of a threat to public health: instead, those figures may represent merely the surface of the problem. The environment and domestic animals seem to have a substantial influence on humans. Studies have indicated that touristic travels to rural areas in countries with a high or unknown prevalence could be contributing to just such an influence [21,37]. In addition, world trade, little control or prevention in the food chain, and permanent close contact with backyard animals in developing countries can increase the risk of zoonotic transmissions with mcr [38].

China ranks first in reporting on studies of E. coli containing mcr, because that country is considered the one with the highest consumption of colistin in agriculture, which circumstance does not apply to certain countries such as the United States, Argentina, and those in the EU that banned its use in animal production and in human treatment [39,40]. Other countries, however, with permissive laws about colistin use have also manifested a higher prevalence of mcr [20,41].

3.2. mcr Variants Worldwide

Since the first report of the mcr-1 gene in China, 10 variants and many sub-variants have been found. Moreover, the greater dissemination of the mcr-1 in bacterial isolates of E. coli may have resulted because that variant was the first one identified, with its initial emergence having been almost a decade before being isolated for the first time [42]. Indeed, retrospective studies revealed that isolates of E. coli had been analyzed from sick pigs within the period from 1991 to 2014 from which animals the mcr genes were first identified [43]. In addition, not all studies that have evaluated colistin resistance have determined the presence of all the reported variants of the mcr genes, where many studies only performed polymerase-chain-reaction assays with specific primers designed to detect a particular variant of the gene. That bias in the screening could well explain why the other variants of the mcr genes (mcr-2–mcr-10) have been less frequently reported [44,45].

Asia and Europe have more recently registered a wide diversity of mcr variants at eight and five, respectively, thus suggesting not only a considerable spread within those continents but also a constantly changing epidemiology. Polymyxins, mainly colistin, are one of the most widely sold antimicrobial groups worldwide [41,46]. That widespread usage is consistent with the diversity of variants founded in pigs in those two continents. This phenomenon can be explained by the continued usage of colistin as a growth promoter by certain countries in Asia and Europe [47]. In Asia, Thailand represents the highest diversity country, having six different variants of mcr. In Europe, Spain was found to have four variants in several studies. Italy is the country with the second highest use of polymyxins in veterinary medicine, which practice could explain why the variants of this gene are widely distributed within that region [48]. Furthermore, some significant studies in Belgium, Italy, and Spain indicated the coexistence of mcr-1, mcr-3, and/or mcr-4 in isolates of E. coli obtained from cattle feces. These findings point to practices that could be responsible for increasing the spread and zoonotic risk in the continent [49–51].

3.3. Present and Future Implications

Different animal species have evidenced a wide distribution of mcr [52–56]. In addition to pigs and chickens, several hosts—such as cows, poultry, and domestic animals like dogs and cats—have been reported to carry the mcr gene in Gram-negative bacteria and then to subsequently transfer colistin resistance to humans. [57–59]. The high prevalence of 15.8% [11.7–20.9] and 14.9% [10.8–20.1] encountered in studies carried out in chickens and pigs, respectively, may have occurred because those animals are widely used for human consumption. This practice should promote a real interest in ensuring safety in the raising of these animals for food worldwide. Consequently, the increasing dispersion and diversity of variants encountered in this systematic review should be considered a red flag. Furthermore, many countries lack data, either due to low resources, the absence of active surveillance programs, or even a vested interest on the part of local governments in not
making public such contraindicated uses of antibiotics by the livestock industry. These findings should constitute issues of major concern that will directly affect the immediate and long-term future implications for veterinary medicine and public health. [60,61].

Because little is known about the prevalence of mcr in the intestinal microbiota of these animals, an evaluation of the presence of these genes in the different food-production chains within the various countries is indeed urgent. Studies have been carried out on the prevalence of mcr in chickens and pigs that point to the livestock industry as the main source responsible for the spread and increase of colistin resistance in enterobacteria [62–64]. In particular, attention should be paid to commensal bacteria such as E. coli with easy inter-host spread and a wide broad capability of horizontal gene transfer. A retrospective study carried out in Italy in 2014 and 2015 reported isolates of colistin-resistant E. coli and Salmonella sp. with mcr in food-producing animals (chickens, pigs, and cattle). That study determined that the bacterial species with the greater resistance to colistin was E. coli, thus underscoring the probability of a horizontal transfer of mcr between commensal bacteria and the main pathogens transmitted by food [58].

Zoonotic pathogens involved in resistance to antimicrobials present in meat foods represent a direct danger to public health [65,66]. The one-health concept cited above recognizes that human health is integrally connected to the health of animals and the environment [67–69]. As stressed throughout this review, a notable prevalence of E. coli with mcr has been evidenced in consumer animals such as pigs and chickens. In contrast, the prevalence in human isolates is described as relatively low, both in community and clinical studies. These data agree with the estimated prevalence obtained by the meta-analysis where chickens and pigs worldwide were found to exhibit higher percentages of mcr than healthy humans and clinical cases. Of interest to us was that the estimated prevalence in all the meta-analyses carried out here was higher than the corresponding gross prevalence, which difference could point to an underestimation of the prevalence of mcr. These data should be considered as a matter of concern for public health in view of the easy zoonotic and environmental transmission [44,45,66,70].

Finally, this study has documented data that seek to help in decision-making to reduce mcrMCRE circulation in the environment and in animals and humans. Governments must need focus on common efforts in the use of antibiotics in animals in the face of the present resistance phenomenon and the continuous increasing demand for animal products for human consumption [71,72]. A significant effort has been made in developed countries to control and reduce the spread of mcr, where a ban on the free use of colistin in animals has apparently reduced the incidence of mcr-1-harboring IncX4-Type plasmids, whose presence is associated with a high dispersal capability in enterobacteria. Notwithstanding, this policy has not yet pervaded the global panorama: indeed, many developing countries—mainly in Africa, South America, and Asia—still manifest weak national drug-regulatory authorities, inefficient antibiotic policies, and erratic and unregulated access to antibiotics.

3.4. Limitations

This study has certain limitations. The first is that only studies with molecular-genetic methods for the detection of mcr resistance are included, with phenotypic methods being excluded because of the discrepancies and problems associated with those studies on the antibiotic colistin. The increase in Gram-negative bacteria with multiple resistances necessitates the use of an accurate method for colistin-susceptibility testing. The European Committee for Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) recommend the standard broth-micro-dilution (BMD) method for testing the minimum inhibitory concentration (MIC) of colistin as the most appropriate. This method was thus the one most frequently used in the studies. Other testing methods—such as disk diffusion, gradient diffusion, the E-test, and agar dilution—are not recommended until further investigative studies on their accuracy have been performed. [73]. The BMD method with colistin, however, was associated with methodologic problems since colistin binds to the plastic of the polystyrene trays, thus reducing the
effective concentration in the broth and consequently altering the MIC values. [74–78]. Recently a joint EUCAST-CLSI working group decided that the recommendations of the International Standardization Organization should be met, with the tests being carried out with colistin sulfate without the addition of surfactants—where those amphipaths do not improve the performance of the assay and in fact act synergistically with colistin [79].

Gradient tests—namely, E-tests, disk diffusion, and semi-automated antimicrobial-susceptibility devices such as VITEK-2 and Thermo Scientific Sensititre—have been widely used in clinical laboratories despite advice from CLSI and EUCAST. A variety of studies comparing the use of different antimicrobial-susceptibility methods to find the most suitable one has determined that gradient tests generally underestimate the MICs of colistin, thus resulting in a significant number of false susceptibilities. These findings substantiated that diffusion tests were not reliable and accordingly led to a recommendation of the use of BMD methods [80,81]. In addition, variations in bacterial promoters are associated with the expression of mcr-1 and consequently with the level of colistin resistance. The presence of the gene per se will not always indicate resistance so that strains harboring the mcr locus can nevertheless be phenotypically sensitive to colistin [82].

Another limitation is that the study does not include the coexistence of genes involved in other types of resistance. Bacteria can exhibit a multiple resistance phenotype due to the accumulation of resistance plasmids, genes encoding the resistance of a specific agent, and/or the action of efflux pumps [83]. These are the main mechanisms of E. coli that contain the mcr gene for manifesting a resistance to other antimicrobials also. The use of colistin as an antibiotic in the last line of treatment for bacteria with multiple resistances may be one of the reasons why most of the isolates that were identified as positive for mcr genes also displayed resistances to other antibiotics. A study carried out in Spain analyzed the co-occurrence of different variants of the mcr-1, mcr-4, and mcr-5 genes in E. coli that presented multiple resistances to other drugs isolated from swine farms. The authors determined that the swine industry was a reservoir of colistin-resistant E. coli, which status was accompanied by other additional risk genes such as the extended-spectrum ß-lactamase (ESBL) and the cefotaxime-hydrolyzing ß-lactamase blaCTXM. Consequently, since pigs are animals for human consumption, they could be spreading a cocktail of multiple resistances [19].

The possession of a wide distribution of ESBL genes may be related to a coexistence with mcr genes because the latter are so widely distributed in the same food-producing animals. This extensive distribution of those genes can be attributed to an inadequate combination of multiple classes of broad-spectrum antibiotics, while the rapid increase in the occurrence of ESBL apparently also enhances the selective pressure for colistin resistance [84]. Colistin and ß-lactams can damage the cell walls of bacteria by disrupting the outer membrane and by inhibiting peptidoglycan synthesis, respectively. Maintaining the integrity of the cell membrane has become the main mechanism for the bacteria to survive the onslaught of antibiotics, which necessity can lead to a high prevalence of positive mcr and ESBL genes isolated. The plasmids that carry the mcr-1 gene in most ESBL isolates are similar to the one that carries the ESBL genes, pHNSHP45. Because of the great resemblance of these resistance loci within the genetic context, the incorporation of ESBL into the bacterial genome increases the probability of the eventual acquisition of the mcr-1 gene in isolates that do not yet possess that locus. Moreover, the study cited also mentions having detected the mcr-1 gene and the blaCTX-M-1 gene together in the same large, conjugated IncHI2-type plasmid [85,86].

Plasmids carrying the blaNDM-1 gene also transport several other genes that confer resistance to all aminoglycosides, macrolides, and sulfamethoxazole, thus, making those isolates resistant to multiple drugs [87]. Plasmids that carry the gene for carbapenemase can carry up to 14 other determining genes for resistance to other antibiotics and transfer this resistance to other bacteria, resulting in multiple resistance phenotypes among which mcr-1 expression has also been present. Because of this association, blaNDM genes have also possibly been identified in many of the isolates that were positive for mcr in the
systematic review studies. A study to identify the co-transfer of those genes revealed the presence of \textit{mcr-1} and \textit{blaNDM-5} in the same hybrid plasmid—\textit{IncX3-X4}—of \textit{E. coli} isolates, thus indicating that the possibility of finding these genes simultaneously in the same microorganism was high [85,88]. The coexistence of \textit{mcr} and the tetracycline-resistance genes \textit{tetA} and \textit{tetB} may have occurred because colistin and tetracycline have been widely used in veterinary medicine and in clinical practice where the dosage and use of one alone has not been adequate. In addition, the selection pressure of the environment can likewise influence the greater spread of these genes [89].

Furthermore, we consider that another limitation of this study is the focus on colistin resistance mediated by only \textit{mcr}. Certain mechanisms of resistance to polymyxins have been described, with the best-known forms involving intrinsic, mutational, and adaptive mechanisms [90]. Because of this heterogeneity, more than one of these mechanisms can possibly be found in a single microorganism; and since certain bacteria can develop antibiotic insensitivity by a process called acquired resistance, while others are naturally resistant to those drugs [91], these additional forms of resistance can explain why \textit{mcr} was not found in all the isolates of \textit{E. coli} that exhibited a resistance to colistin identified by solely phenotypic methods.

4. Materials and Methods

4.1. Search Strategies

The systematic review of the literature and the meta-analysis were carried out according to the recommendations of Sagoo, et al. (2009) and as described in Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The following search strategy was applied: in the PubMed database: through the use of the Boolean operator AND with the terms “\textit{Escherichia coli}” OR “\textit{E. coli}” AND “colistin” OR “polymyxins” introduced in the advanced search bar, and the filters activated for the period from 31 December 2014, to March 2021.

4.2. Criteria for the Selection of the Studies

The selection of the studies was carried out by two separate reviewers (SS and MV) using the Rayyan QCRI bibliographic manager. Only English-language full-text articles were selected in three phases. The first phase consisted in the removal of all repeated studies. The second phase consisted of the exclusion of articles from the title and abstract review according to the following criteria: (1) studies whose hosts were not pigs, chickens, and/or humans, (2) single-case studies, (3) studies where the bacterial species was different from \textit{E. coli}, (4) studies in which colistin resistance was mediated by a different mechanism from \textit{mcr} genes, (5) Interviews, letters, reviews, or editorials not presenting original data.

The third phase was applied when full texts were read and consisted of a study selection according to the following inclusion criteria: (1) studies where the sampling methods were randomized for all participants, (2) prevalence reports of \textit{mcr}-mediated colistin-resistant \textit{E. coli} (\textit{mcrMCRE}), where resistance was identified at least by molecular-genetic methods for the presence of \textit{mcr}, (3) clinical studies that included the prevalence of \textit{mcrMCRE}, (4) animal studies reporting \textit{mcrMCRE} in which samples were taken from live animals, feces, or carcasses before the processing of meat products. Studies with only phenotypic determinations were left out since we did not know if the \textit{mcr} gene or chromosomal mutations were involved.

4.3. Database

The studies included were divided into two categories: (i) Community studies: those involving pigs, chickens, and healthy humans and (ii) Clinical studies: any investigation related to the hospital environment such as clinical, surgical, and ambulatory cases. For every article selected the following items were collected and introduced into a database in Excel: Title; author(s); year of publication; country; total number of samples collected (n); number of \textit{E. coli} isolates; prevalence of colistin-resistant \textit{E. coli}; and prevalence of
mcrMCRE, variants of the mcr gene, the host animal, the sample origin, the antimicrobial-susceptibility method used (phenotypic method), or the means of mcr-gene identification (molecular-genetic methodology).

4.4. Statistical and Meta-Analysis Approach

Descriptive statistics were performed to obtain the crude prevalence of the mcr gene according to the continent and host studied. The meta-analysis for the estimation of mcr-mediated colistin resistance in E. coli was conducted by means of the “meta” package of the R software. A separate meta-analysis was performed for each of the chicken, pig, and human hosts in the community and clinical studies in each region. In total, eight meta-analyses (four meta-analyses each for the origin of the samples and for each continent) were conducted based on a random-effects model. For each prevalence reported, the 95% exact binomial-confidence intervals (95% CI) were calculated. Publication bias was also calculated by a funnel-plot evaluation.

5. Conclusions

The results presented here demonstrate a wide dispersion and diversity of mcr genes in 54 countries on five continents. We also demonstrate that the majority of the mcr genes are in the food chain and most probably play a major role in the dissemination of mcr to isolates from humans.

In response to the rapid spread of mcr among different hosts, a regular surveillance for colistin resistance is needed to support the practice of evidence-based medicine and a one-health approach.

This study supports the thesis that, since within a common ecosystem microorganisms can affect humans and animals with the same pathology, to contain those contaminants effectively the adoption of an approach that unites animal, human, and environmental health to prevent zoonosis outbreaks and food-safety problems is vitally necessary. Accordingly, an understanding of the epidemiology of colistin-resistant E. coli will both facilitate the possibility of formulating prevention protocols and serve to promote comprehensive surveillance worldwide.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pathogens11060659/s1, Figures S1–S8: Forest plot showing the prevalence of mcrMCRE. The X-axis represents the prevalence proportion of the bacteria reported in the individual studies, which are shown on the Y-axis, accompanied by the proportion range of the 95% confidence interval, the proportion of the point estimate and the proportion of the weight of each study in the meta-analysis. The gray squares are the graphical representation of the point estimate for each study, and the line through them represents the 95% confidence interval. The blue parallelogram graphically represents the pooled point estimate of the different groups of the data (Figure S1, Asia; Figure S2, Europe; Figure S3, Africa; Figure S4, The Americas; Figure S5, chickens; Figure S6, Pigs; Figure S7, Healthy humans and Figure S8 clinical samples). Tables S1–S4: Studies included in systematic review and meta-analysis for each sample type (Table S1, chickens; Table S2, pigs; Table S3, healthy humans; and Table S4, clinical samples); Table S5: Prevalence of mcr genes in different continents distributed in the selected studies according of data categories. References [92–261] are cited in the supplementary materials.

Author Contributions: Conceptualization, C.B.-C. and M.C.-A.; methodology, M.S.S. and M.J.V.; software, M.S.S., M.J.V. and M.C.-A. validation, C.B.-C., M.C.-A. and M.C.; formal analysis, C.B.-C.; investigation, C.B.-C. and M.S.S.; data curation, M.S.S. and M.J.V.; writing—original draft preparation, C.B.-C.; writing—review and editing, J.H.d.W. and Y.Y.; supervision, M.C. and J.H.d.W. All authors have read and agreed to the published version of the manuscript.

Funding: The APC was funded by Universidad de las Americas, Dirección General de Investigación y Vinculación.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.
Acknowledgments: Adriana Gallegos-Ordoñez, I thank Adriana for her company, understanding and valuable help during long nights of work. Donald F. Haggerty, a retired academic investigator and native English speaker, edited the final version of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Elbediwi, M.; Li, Y.; Paudyal, N.; Pan, H.; Li, X.; Xie, S.; Rajkovic, A.; Feng, Y.; Fang, W.; Rankin, S.C.; et al. Global Burden of Colistin—Resistant Bacteria: Mobilized Colistin Resistance Genes Study (1980–2018). *Microorganisms* 2019, 7, 461. [CrossRef] [PubMed]

2. Lutgring, J.; Machado, M.J.; Benahmed, F.; Conville, P.; Shawar, R.; Patel, J.; Brown, A.; Kraft, C.S. FDA-CDC Antimicrobial Resistance Isolate Bank: A Publicly Available Resource to Support Research, Development, and Regulatory Requirements. *J. Clin. Microbiol.* 2022, 56, e01415–e01417. [CrossRef] [PubMed]

3. Prestinaci, F.; Pezzotti, P.; Pantosti, A. Antimicrobial Resistance: A Global Multifaceted Phenomenon. *Pathog. Glob. Health* 2015, 109, 309–318. [CrossRef] [PubMed]

4. Spellberg, B.; Blaser, M.; Guidos, R.J.; Bradley, H.W.; Bradley, J.S.; Eisenstein, B.I.; Gerding, D.; Lynfield, R.; Reller, L.B.; Rex, J.; et al. Combating Antimicrobial Resistance: Policy Recommendations to Save Lives. *Clin. Infect. Dis.* 2011, 52 (Suppl. 5), 397–428. [CrossRef] [PubMed]

5. Sarkar, S.; Hermes DeSantis, E.R.; Kuper, J. Resurgence of Colistin Use. *Am. J. Health Pharm.* 2016, 10, R27. [CrossRef] [PubMed]

6. Falagas, M.E.; Kasiakou, S.K. Toxicity of Polymyxins: A Systematic Review of the Evidence from Old and Recent Studies. *Crit. Care* 2006, 10, R27. [CrossRef] [PubMed]

7. Kift, E.V.; Chb, M.B.; Hons, B.; Maartens, G.; Chb, M.B.; Med, M.I.; Bamford, C.; Chb, M.B.; Micro, M.M. Systematic Review of the Evidence for Rational Dosing of Colistin. *S. Afr. Med. J.* 2014, 104, 183–186. [CrossRef]

8. Falagas, M.E.; Kasiakou, S.K. Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections. *Clin. Infect. Dis.* 2005, 40, 1333–1342. [CrossRef] [PubMed]

9. Mohsin, M.; Van Boeckel, T.P.; Saleemi, M.K.; Umair, M.; Naseem, M.N.; He, C.; Khan, A.; Laxminarayan, R. Excessive Use of Medically Important Antimicrobials in Food Animals in Pakistan: A Five-Year Surveillance Survey. *Glob. Health Action* 2019, 12 (Suppl. 1), 1697541. [CrossRef]

10. Boonyasiri, A.; Tangkoskul, T.; Seenama, C.; Tiengrim, S.; et al. Prevalence of Antibiotic Resistant Bacteria in Healthy Adults, Foods, Food Animals, and the Environment in Selected Areas in Thailand. *Pathog. Glob. Health* 2014, 108, 235–245. [CrossRef]

11. Bonten, M.; Johnson, J.R.; Van Den Biggelaar, A.H.J.; Georgalis, L.; Geurtsen, J.; De Palacios, P.I.; Ibarra, M.; Sabin, R.; et al. Acquired Resistance to Colistin via Chromosomal and Plasmid-Mediated Mechanisms in Klebsiella Pneumoniae. *Infect. Microbes Dis.* 2019, 72, 1211–1219. [CrossRef] [PubMed]

12. Begier, E.; Rosenthal, N.A.; Gurtman, A.; Kartashov, A.; Donald, R.G.K.; Lockhart, S.P. Epidemiology of Invasive Escherichia coli Infection and Antibiotic Resistance Status among Patients Treated in US Hospitals: 2009–2016. *Clin. Infect. Dis.* 2021, 73, 565–574. [CrossRef] [PubMed]

13. Paitan, Y. Current Trends in Antimicrobial Resistance of Escherichia coli. *Curr. Top. Microbiol. Immunol.* 2018, 416, 81–211. [CrossRef]

14. Poirel, L.; Madec, J.; Lupo, A.; Schink, A.; Kieffer, N.; Nordmann, P.; Schwarz, S. Antimicrobial Resistance in Escherichia coli. *Microbiol. Spectr.* 2018, 6, 1–27. [CrossRef]

15. Berglund, B. Acquired Resistance to Colistin via Chromosomal and Plasmid-Mediated Mechanisms in Klebsiella Pneumoniae. *Infect. Microbes Dis.* 2019, 72, 10–19. [CrossRef] [PubMed]

16. Liu, H.; Zhe, B.; Liang, B.; Xu, X.; Qu, S.; Jia, L.; Li, P.; Yang, L.; Li, Y.; Xiang, Y.; et al. A Novel Mcr-1 Variant Carried by an IncI2-Type Plasmid Identified from a Multidrug Resistant Enterotoxigenic Escherichia coli Resistance Isolate Bank: A Publicly Available Resource to Support Research, Development, and Regulatory Requirements. *Lancet Infect. Dis.* 2016, 16, 161–168. [CrossRef]

17. Baron, S.; Hadjdaj, L.; Rolain, J.M.; Olaitan, A.O. Molecular Mechanisms of Polymyxin Resistance: Knowns and Unknowns. *Int. J. Antimicrob. Agents* 2016, 48, 583–591. [CrossRef]

18. Liu, Y.; Wang, Y.; Walsh, T.R.; Yi, L.; Zhang, R.; Spencer, J.; Dui, Y.; Tian, G.; Dong, B.; Huang, X.; et al. Emergence of Plasmid-Mediated Colistin Resistance Mechanism MCR-1 in Animals and Human Beings in China: A Microbiological and Molecular Biological Study. *Lancet Infect. Dis.* 2016, 16, 161–168. [CrossRef]

19. García, V.; García-Meníno, I.; Mora, A.; Flament-Simon, S.C.; Díaz-Jíménez, D.; Blanco, J.E.; Alonso, M.P.; Blanco, J. Co-Occurrence of Mcr-1, Mcr-4 and Mcr-5 Genes in Multidrug-Resistant ST10 Enterotoxigenic and Shiga Toxin-Producing Escherichia coli in Spain (2006–2017). *Int. J. Antimicrob. Agents* 2018, 52, 104–108. [CrossRef] [PubMed]

20. Irrgang, A.; Roschanski, N.; Tenhagen, B.; Grobbel, M. Prevalence of Mcr-1 in E. coli from Livestock and Food in Germany, 2010–2015. *PloS ONE* 2016, 11, e0159863. [CrossRef]

21. Von Wintersdorff, C.J.H.; Wolffs, P.F.G.; Van Nierkirk, J.M.; Beuken, E.; Van Alphen, L.B.; Stobberingh, E.E.; Lashof, A.M.L.O.; Hoebe, C.J.P.A.; Savelkoul, P.H.M.; Penders, J. Detection of the Plasmid-Mediated Colistin-Resistance Gene Mcr-1 in Faecal Metagenomes of Dutch Travellers. *J. Antimicrob. Chemother.* 2016, 71, 3416–3419. [CrossRef] [PubMed]
22. Wang, C.; Feng, Y.; Liu, L.; Wei, L.; Kang, M.; Zong, Z. Identification of Novel Mobile Colistin Resistance Gene Mcr-10. Emerg. Microbes Infect. 2020, 9, 508–516. [CrossRef]

23. Rebejo, A.R.; Borotalia, V.; Kjeldgaard, J.S.; Pedersen, S.K.; Leekitcharoensophon, P.; Hansen, I.M.; Guerra, B.; Malorny, B.; Borowiak, M.; Hammerl, J.A.; et al. Multiplex PCR for Detection of Plasmid-Mediated Mcr-4 and Mcr-5 for Surveillance Purposes. Eurosurveillance 2018, 23, 17-00672. [CrossRef]

24. Xavier, B.B.; Lammens, C.; Ruhal, R.; Malhotra-Kumar, S.; Butaye, P.; Goossens, H.; Malhotra-Kumar, S. Identification of a Novel Plasmid-Mediated Colistin Resistance Gene, Mcr-2, in Escherichia Coli, Belgium, June 2016. Eurosurveillance 2016, 21, 6–11. [CrossRef] [PubMed]

25. Borowiak, M.; Baumann, B.; Fischer, J.; Thomas, K.; Deneke, C.; Hammerl, J.A.; Szabo, I.; Malorny, B. Development of a Novel Mcr-6 to Mcr-9 Multiplex PCR and Assessment of Mcr-1 to Mcr-9 Occurrence in Colistin-Resistant Salmonella Enterica Isolates from Environment, Feed, Animals and Food (2011–2018) in Germany. Front. Microbiol. 2020, 11, 80. [CrossRef]

26. Roer, L.; Hansen, F.; Stegger, M.; Sönksen, U.W.; Hasman, H.; Hammerum, A.M. Novel Mcr-3 Variant, Encoding Mobile Colistin Resistance, in an ST131 Escherichia Coli Isolate from Bloodstream Infection, Denmark, 2014. Eurosurveillance 2017, 22, 30584. [CrossRef]

27. Jeannot, K.; Bolard, A.; Plésiat, P. Resistance to Polymyxins in Gram-Negative Organisms. Int. J. Antimicrob. Agents 2017, 49, 526–535. [CrossRef] [PubMed]

28. Quesada, A.; Ugarte-Ruiz, M.; Iglesias, M.R.; Porrero, M.C.; Martínez, G.; Flores-Cuadrado, D.; Campos, M.J.; García, M.; Piriz, S.; Sáez, J.L.; et al. Detection of Plasmid Mediated Colistin Resistance (MCR-1) in Escherichia coli and Salmonella enterica Isolated from Poultry and Swine in Spain. Rev. Vet. Sci. 2016, 105, 134–135. [CrossRef]

29. Shen, Z.; Wang, Y.; Shen, Y.; Shen, J.; Wu, C. Early Emergence of Mcr-1 in Escherichia Coli from Food-Producing. Lancet Infect. Dis. 2016, 16, 293. [CrossRef]

30. Organización Mundial de la Salud; Organización Panamericana de la Salud. Enterobacterias Con Resistencia Transferible a Colistina, Implicaciones Para La Salud Publica en Las Américas. Boletín Orgánico Mund. Salud 2016, 1, 1–5.

31. Elias, C.; Moja, L.; Mertz, D.; Loeb, M.; Forte, G.; Magrini, N. Guideline Recommendations and Antimicrobial Resistance: The Need for a Change. BMJ Open 2017, 7, e016264. [CrossRef]

32. Felmingham, D. The Need for Antimicrobial Resistance Surveillance. J. Antimicrob. Chemother. 2002, 50 (Suppl. 1), 1–7. [CrossRef]

33. Nations, U.; Assembly, G.; York, N.; Humphreys, G.; Fleck, F. United Nations Meeting on Antimicrobial Resistance. Lancet Infect. Dis. 2016, 16, 638–639.

34. Wang, R.; Liu, Y.; Zhang, Q.; Jin, L.; Wang, Q.; Zhang, Y.; Wang, X.; Hu, M.; Li, L.; Qi, J.; et al. The Prevalence of Colistin Resistance in Escherichia coli with Chromosomally Carried mcr-1 in Healthy Residents in Vietnam Takahiro. mSphere 2020, 5, e00117-20. [CrossRef] [PubMed]

35. Gilrane, V.L.; Lobo, S.; Huang, W.; Zhuge, J.; Yin, C.; Chen, D.; Alvarez, K.J.; Budhai, A.; Nadelman, I.; Dimitrova, N.; et al. Complete Genome Sequence of a Colistin-Resistant Escherichia coli Strain Harboring mcr-1 on an IncHI2 Plasmid in the United States. Genome Announce. 2017, 5, 10–11. [CrossRef] [PubMed]

36. Matamoros, S.; Van Hattem, J.M.; Arcilla, M.S.; Willemse, N.; Melles, D.C.; Penders, J.; Vinh, T.N.; Thi Hoa, N.; Bootsma, M.C.J.; Van Genderen, P.J.; et al. Global Phylogenetic Analysis of Escherichia Coli and Plasmids Carrying the MCR-1 Gene Indicates Bacterial Diversity but Plasmid Restriction. Sci. Rep. 2017, 7, 15364. [CrossRef]

37. Yamaguchi, T.; Kawahara, R.; Hamamoto, K.; Hirai, I.; Khong, T.; Nguyen, N. High Prevalence of Colistin-Resistant Escherichia coli with Chromosomally Carried mcr-1 in Healthy Residents in Vietnam Takahiro. mSphere 2020, 5, e00117-20. [CrossRef] [PubMed]

38. Luo, Q.; Wang, Y.; Xiao, Y. Prevalence and Transmission of Mobilized Colistin Resistance (Mcr) Gene in Bacteria Common to Animals and Humans. Biosaf. Health 2020, 2, 71–78. [CrossRef]

39. Walia, K.; Sharma, M.; Vijay, S.; Shone, B.R. Understanding Policy Dilemmas around Antibiotic Use in Food Animals & Offering Potential Solutions. Indian J. Med. Res. 2019, 7, 102–118. [CrossRef]

40. Hu, Y.J.; Cowling, B.J. Reducción Del Uso de Antibióticos En El Ganado, China. Bull. World Health Organ. 2020, 98, 360–361. [CrossRef]

41. Agency European Medicines. Sales of Veterinary Antimicrobial Agents in 31 European Countries in 2017 Trends from 2010 to 2017, Ninth ESVAC Report. OJL 2017, 135, 1–109.

42. Wang, R.; Van Dorp, L.; Shaw, L.P.; Bradley, P.; Wang, Q.; Wang, X.; Jin, L.; Zhang, Q.; Liu, Y.; Ruek, A.; et al. The Global Distribution and Spread of the Mobilized Colistin Resistance Gene mcr-1. Nat. Commun. 2018, 9, 1179. [CrossRef]

43. Kusumoto, M.; Ogura, Y.; Gotob, Y.; Iwata, T.; Hayashi, T.; Akiba, M. Colistin-Resistant mcr-1-Positive Pathogenic Escherichia coli in swine, Japan, 2007–2014. Emerg. Infect. Dis. 2016, 22, 1315–1317. [CrossRef]

44. Joshi, P.R.; Thummeepak, R.; Paudel, S.; Acharya, M.; Pradhan, S.; Banjara, M.R.; Leungtongkam, U.; Sithisak, S. Molecular Characterization of Colistin-Resistant Escherichia coli Isolated from Chickens: First Report from Nepal. Microb. Drug Resist. 2019, 25, 846–854. [CrossRef]

45. Belaynehe, K.M.; Shin, S.W.; Park, K.Y.; Jang, J.Y.; Won, H.G.; Yoon, I.J.; Yoo, H.S. Emergence of Mcr-1 and Mcr-3 Variants Coding for Plasmid-Mediated Colistin Resistance in Escherichia coli Isolates from Food-Producing Animals in South Korea. Int. J. Infect. Dis. 2018, 72, 22–24. [CrossRef] [PubMed]
70. Vinh Trung, N.; Matamoros, S.; Carrique-Mas, J.J.; Nghia, N.H.; Thi Nhung, N.; Thi Bich Chieu, T.; Huynh Mai, H.; van Rooijen, W.; Campbell, J.; wagonaar, J.A.; et al. Zoonotic Transmission of mcr-1 Colistin Resistance Gene from Small-Scale Poultry Farms, Vietnam. Emerg. Infect. Dis. 2017, 23, 529–532. [CrossRef]

71. Al-Tawfiq, J.A.; Laxminarayan, R.; Mendelson, M. How Should We Respond to the Emergence of Plasmid-Mediated Colistin Resistance in Humans and Animals? Int. J. Infect. Dis. 2017, 54, 77–84. [CrossRef][PubMed]

72. Caniaux, I.; van Belkum, A.; Zambardi, G.; Poirel, L.; Gross, M.F. MCR: Modern Colistin Resistance. Eur. J. Clin. Microbiol. Infect. Dis. 2017, 36, 415–420. [CrossRef]

73. The European Commitee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute, A. Recommendations for MIC Determination of Colistin (Polymyxin E) as Recommended by the Joint CLSI-EUCAST Polymyxin Breakpoints Working Group. EUCAST. 2016. Available online: http://www.biocollections.co.uk/files/merlin/Recommendations_for_MIC_determination_of_colistin_March_2016.pdf (accessed on 1 May 2022).

74. Osei Sekyere, J. MCR Colistin Resistance Gene: A Systematic Review of Current Diagnostics and Detection Methods. Microbiology Open 2019, 8, e00682. [CrossRef]

75. Jayol, A.; Nordmann, P.; Andrée, C.; Poirel, L.; Dubois, V. Evaluation of Three Broth Microdilution Systems to Determine Colistin Susceptibility of Gram–Negative Bacilli. J. Antimicrob. Chemother. 2018, 73, 1272–1278. [CrossRef][PubMed]

76. Haiziq, M.; Momin, F.A.; Bean, D.C.; Hendriksen, R.S.; Haenni, M.; Phee, L.M.; Wareham, D.W. CHROMagar COL-APSE: A Selective Bacterial Culture Medium for the Isolation and Differentiation of Colistin-Resistant Gram-Negative Pathogens. J. Med. Microbiol. 2017, 66, 1554–1561. [CrossRef]

77. Jayol, A.; Nordmann, P.; Lehours, P.; Poirel, L.; Dubois, V. Comparison of Methods for Detection of Plasmid-Mediated and Chromosomally Encoded Colistin Resistance in Enterobacteriaceae. Clin. Microbiol. Infect. 2018, 24, 175–179. [CrossRef]

78. Chew, K.L.; La, M.-V.; Lin, R.T.; Teo, J.W. Colistin and Polymyxin B Susceptibility Testing for Carbapenem-Resistant and mcr-Positive Enterobacteriaceae: Comparison of Sensititre, MicroScan, Vitek 2, and Etest with Broth Microdilution. J. Clin. Microbiol. 2017, 55, 2609–2616. [CrossRef]

79. Sader, H.S.; Rhomberg, P.R.; Flam, R.K.; Jones, R.N. Use of a Surfactant (Polyisorbate 80) to Improve MIC Susceptibility Testing Results for Polymyxin B and Colistin. Diagn. Microbiol. Infect. Dis. 2012, 74, 412–414. [CrossRef][PubMed]

80. Matuschek, E.; Āhmans, J.; Webster, C.; Kahrlmner, G. Antimicrobial Susceptibility Testing of Colistin—Evaluation of Seven Commercial MIC Products against Standard Broth Microdilution for Escherichia coli, Klebsiella Pneumoniae, Pseudomonas Aeruginosa, and Acinetobacter spp. Clin. Microbiol. Infect. 2018, 24, 865–870. [CrossRef]

81. Galani, I.; Kontopidou, F.; Souli, M.; Rekatsina, P.; Koratzanis, E.; Deliolanis, J.; Giamarelou, H. Colistin Susceptibility Testing by Etest and Disk Diffusion Methods. J. Antimicrob. Agents 2008, 31, 434–439. [CrossRef]

82. Lu, S.; Li, D.; Wang, L.; Yi, C.; Wang, M.; Yang, F. Promoter Variations Associated with Expression of Mcr-1 Gene and Level of Colistin Resistance. Int. J. Antimicrob. Agents 2021, 58, 106371. [CrossRef]

83. Nikaido, H. Multidrug Resistance in Bacteria. Annu. Rev. Biochem. 2009, 78, 119–146. [CrossRef]

84. Wu, C.; Wang, Y.; Shi, X.; Wang, S.; Ren, H.; Shen, Z.; Wang, Y.; Lin, J.; Wang, S. Rapid Rise of the ESBL and MCR-1 Genes in Escherichia coli from Healthy Broilers in Egypt: Emergence of Colistin-Resistant and Extended-Spectrum β-Lactamase-Producing Escherichia coli. Gut Pathog. 2018, 10, 39. [CrossRef]
95. Perreten, V.; Strauss, C.; Collaud, A.; Gerber, D. Colistin Resistance Gene Mcr-1 in Avian-Pathogenic Escherichia Coli in South Africa. *Antimicrob. Agents Chemother.* 2016, 60, 4414–4415. [CrossRef]

96. Hassen, B.; Abbassi, M.S.; Ruiz-Ripa, L.; Mama, O.M.; Hassen, A.; Torres, C.; Hammami, S. High Prevalence of Mcr-1 Encoding Colistin Resistance and First Identification of BlaCTX-M-55 in ESBL/CMY-2-Producing Escherichia Coli Isolated from Chicken Faeces and Retail Meat in Tunisia. *Int. J. Food Microbiol.* 2020, 318, 108478. [CrossRef]

97. Learning, M.; Cookbook, R. The Emergence of Colistin-Resistant Escherichia Coli in Chicken Meats in Nepal. *FEMS Microbiol. Lett.* 2019, 366, fnz237.

98. Atterby, C.; Osbjer, K.; Tepper, V.; Rajala, E.; Hernandez, J.; Seng, S.; Holl, D.; Bonnedahl, J.; Börjesson, S.; Magnrusson, U.; et al. Carriage of Carbapenemase- and Extended-Spectrum Cephalosporinase-Producing Escherichia coli and Klebsiella pneumoniae in Humans and Livestock in Rural Cambodia; Gender and Age Differences and Detection of BlaOXA-48in Humans. *Zoonoses Public Health.* 2019, 66, 603–617. [CrossRef] [PubMed]

99. Muktan, B.; Shrestha, U.T.; Dhungel, B.; Mishra, B.C.; Shrestha, N.; Adhikari, N.; Banjara, M.R.; Adhikari, B.; Rijal, K.R.; Ghimire, P. Plasmid Mediated Colistin Resistant mcr-1 and Co-Existence of OXA-48 among Escherichia coli from Clinical and Poultry Isolates: First Report from Nepal. *Gut Pathog.* 2020, 12, 44. [CrossRef] [PubMed]

100. Dhaouadi, S.; Soufi, L.; Hamza, A.; Fedida, D.; Zied, C.; Awadhi, E.; Mtabaa, M.; Hassen, B.; Cherif, A.; Torres, C.; et al. Co-Occurrence of Mcr-1 Mediated Colistin Resistance and β-Lactamase-Encoding Genes in Multidrug-Resistant Escherichia Coli from Broiler Chickens with Colibacillosis in Tunisia. *J. Glob. Antimicrob. Resist.* 2020, 22, 538–545. [CrossRef] [PubMed]

101. Bista, S.; Shrestha, U.T.; Dhungel, B.; Koirala, P.; Kompo, T.; Shrestha, N.; Adhikari, N.; Joshi, D.; Banjara, M.; Adhikari, B.; et al. Detection of Plasmid-Mediated Colistin Resistant mcr-1 Gene in Escherichia coli isolated from Infected Chicken Livers in Nepal. *Animals.* 2020, 10, 2060. [CrossRef]

102. Ngbede, E.O.; Poudel, A.; Kalalah, A.; Yang, Y.; Adekanmbi, F.; Adikwu, A.A.; Adamu, A.M.; Mamfe, L.M.; Daniel, S.T.; Useh, N.M.; et al. Identification of Mobile Colistin Resistance Genes (mcr-1, mcr-3 and mcr-8.1) in Enterobacteriaceae and Alcaligenes Faecalis of Human and Animal Origin, Nigeria. *Int. J. Antimicrob. Agents.* 2020, 56, 106108. [CrossRef] [PubMed]

103. Büdel, T.; Kuenzli, E.; Campos-Madueno, E.I.; Mohammed, A.H.; Hassan, N.K.; Zinsstag, J.; Hatz, C.; Endimiani, A. On the Island of Zanzibar People in the Community Are Frequently Colonized with the Same MDR Enterobacterales Found in Poultry and Retained Chicken Meat. *J. Glob. Antimicrob. Chemother.* 2020, 75, 2432–2441. [CrossRef] [PubMed]

104. Dominguez, J.E.; Redondo, L.M.; Figueroa Espinoso, R.A.; Cejas, D.; Gutkind, G.O.; Chacana, P.A.; Di Conza, J.A.; Fernández Miyakawa, M.E. Simultaneous Carriage of mcr-1 and Other Antimicrobial Resistance Determinants in Escherichia coli from Poultry. *Front. Microbiol.* 2018, 9, 1679. [CrossRef]

105. Dominguez, J.E.; Figueroa Espinoso, R.A.; Redondo, L.M.; Cejas, D.; Gutkind, G.O.; Chacana, P.A.; Di Conza, J.A.; Fernández-Miyakawa, M.E. Plasmid-Mediated Colistin Resistant mcr-1 Gene Recovered from Healthy Poultry. *Rev. Argent. Microbiol.* 2017, 49, 297–298. [CrossRef]

106. Monte, D.F.; Mem, A.; Fernandes, M.R.; Cerdeira, L.; Esposito, F.; Galvão, J.A.; Franco, B.D.G.M.; Lincopan, N.; Landgraf, M. Chicken Meat as a Reservoir of Colistin-Resistant Escherichia coli Strains Carrying mcr-1 Genes in South America. *Antimicrob. Agents Chemother.* 2017, 61, e02718-16. [CrossRef]

107. Fernandes, M.R.; Moura, Q.; Esposito, F.; Lincopan, N. Authors’ Reply: Escherichia Coli Harbouring mcr-1 Gene Isolated from Poultry Not Exposed to Polymyxins in Brazil. *Eurosurveillance.* 2016, 21, 30267. [CrossRef]

108. Vounba, P.; Rahouma, M.; Arsenault, J.; Bada Alambédjì, R.; Fravallo, P.; Fairbrother, J.M. Prevalence of Colistin Resistance and Mcr-1/Mcr-2 Genes in Extended-Spectrum β-Lactamase/β-Lactamase-Encoding Genes in Multidrug-Resistant Escherichia Coli Isolated from Chickens in Canada, Senegal and Vietnam. *J. Glob. Antimicrob. Resist.* 2019, 19, 222–227. [CrossRef]

109. Yamamoto, Y.; Calvopina, M.; Izurieta, R.; Villacres, I.; Kawahara, R. Colistin Resistant Escherichia coli with Mcr Genes in the Livestock of Rural Small-Scale Farms in Ecuador. *BMC Res. Notes.* 2019, 12, 121. [CrossRef] [PubMed]

110. Säidenberg, A.B.S.; Stegger, M.; Price, L.B.; Johannesen, T.B.; Aziz, M.; Cunha, M.P.; Moreno, A.M.; Knöbl, T. Mcr-Positive Escherichia Coli ST131-H22 from Poultry in Brazil. *Emerg. Infect. Dis.* 2020, 26, 1951–1954. [CrossRef]

111. Coppola, N.; Freire, B.; Umpiérrez, A.; Cordeiro, N.F.; Avila, P.; Trencli, G.; Castro, G.; Casaux, M.L.; Fraga, M.; Zunino, P.; et al. Transferable Resistance to Highest Priority Critically Important Antibiotics for Human Health in Escherichia Coli Strains Obtained from Livestock Feces in Uruguay. *Front. Vet. Sci.* 2020, 7, 588919. [CrossRef]

112. Eltai, N.O.; Abdifarag, E.A.; Al-Romaihi, H.; Wehedy, E.; Mahmoud, M.H.; Alawad, O.K.; Al-Hajri, M.M.; Thanì, A.A.A.L.; Yassine, H.M. Antibiotic Resistance Profile of Commensal Escherichia coli Isolated from Broiler Chickens in Qatar. *J. Food Prot.* 2018, 81, 302–307. [CrossRef] [PubMed]

113. Wang, X.; Wang, Y.; Wang, Y.; Zhang, S.; Shen, Z.; Wang, S. Emergence of the Colistin Resistance Gene Mcr-1 and Its Variant in Several Uncommon Species of Enterobacteriaceae from Commercial Poultry Farm Surrounding Environments. *Vet. Microbiol.* 2018, 219, 161–164. [CrossRef]

114. Hmede, Z.; Kassem, I.I. The Colistin Resistance Gene Mcr-1 Is Prevalent in Commensal Escherichia coli Isolated from Preharvest Poultry in Lebanon. *Antimicrob. Agents Chemother.* 2018, 62, e01304-18. [CrossRef] [PubMed]

115. Obsaki, Y.; Hayashi, W.; Saito, S.; Osaka, S.; Taniguchi, Y.; Koide, S.; Kawamura, K.; Nagano, Y.; Arakawa, Y.; Nagano, N. First Detection of an Escherichia Coli Strain Harboring the Mcr-1 Gene in Retail Domestic Chicken Meat in Japan. *Jpn. J. Infect. Dis.* 2017, 70, 590–592. [CrossRef]
116. Barbieri, N.L.; Nielsen, D.W.; Wannemuehler, Y.; Cavender, T.; Hussein, A.; Yan, S.G.; Nolan, L.K.; Logue, C.M. Mcr-1 Identified in Avian Pathogenic Escherichia coli (APEC). *PloS One* **2017**, *12*, e0172997. [CrossRef]

117. Yang, Y.Q.; Li, Y.X.; Song, T.; Yang, X.Y.; Jiang, W.; Zhang, A.Y.; Guo, X.Y.; Liu, B.H.; Wang, Y.X.; Lei, C.W.; et al. Colistin Resistance Gene Mcr-1 and Its Variant in Escherichia coli Isolates from Chickens in China. *Antimicrob. Agents Chemother.* **2017**, *61*, e01204-16. [CrossRef] [PubMed]

118. Wang, Y.; Zhang, R.; Li, J.; Wu, Z.; Yin, W.; Schwarz, S.; Tyrrell, J.M.; Zheng, Y.; Wang, S.; Shen, Z.; et al. Comprehensive Resistome Analysis Reveals the Prevalence of NDM and MCR-1 in Chinese Poultry Production. *Nat. Microbiol.* **2017**, *2*, 16260. [CrossRef] [PubMed]

119. Liu, B.T.; Song, F.J.; Zhou, M.; Di Zhang, Q.; Shan, H. High Incidence of Escherichia coli Strains Co-harboring Mcr-1 and BlaNDM from Chickens. *Antimicrob. Agents Chemother.* **2017**, *61*, e02347-16. [CrossRef] [PubMed]

120. Nakayama, T.; Jinmai, M.; Kawahara, R.; Diep, K.T.; Thang, N.N.; Hoa, T.T.; Hanh, L.K.; Khai, P.N.; Sumimura, Y.; Yamamoto, Y. Frequent Use of Colistin-Based Drug Treatment to Eliminate Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Backyard Chicken Farms in Thai Binh Province, Vietnam. *Trop. Anim. Health Prod.* **2017**, *49*, 31–37. [CrossRef] [PubMed]

121. Lv, J.; Mohsin, L.; Lei, S.; Srinivasas, S.; Wiqar, R.; Lin, J.; Feng, Y. Discovery of a Mcr-1-Bearing Plasmid in Commensal Colistin-Resistant Escherichia coli from Healthy Broilers in Faisalabad, Pakistan. *Virulence* **2018**, *9*, 994–999. [CrossRef]

122. Song, Y.; Lu, Z.; Zhang, Y.; Dai, Y.; Wang, P.; Feng, C.; Liu, M.; Sun, S.; Xie, Z.; Wang, F. Prevalence and Characteristics of Multidrug-Resistant Mcr-1-Positive Escherichia coli Isolates from Broiler Chickens in Tai’an, China. *Poult. Sci.* **2020**, *99*, 1117–1123. [CrossRef]

123. Zhuge, X.; Jiang, M.; Tang, F.; Sun, Y.; Ji, Y.; Xue, F.; Ren, J.; Zhu, W.; Dai, J. Avian-Source Mcr-1-Positive Escherichia coli Isolates from Fresh Vegetables and Healthy Food Animals in South Korea. *Int. J. Infect. Dis.* **2019**, *80*, 25–29. [CrossRef] [PubMed]

124. Malhotra-Kumar, S.; Xavier, B.B.; Das, A.J.; Lammens, C.; Hoang, H.T.T.; Pham, N.T.; Goossens, H. Colistin-Resistant Escherichia coli on a Large-Scale Chicken Farm in Vietnam. *Lancet Infect. Dis.* **2016**, *16*, 286–287. [CrossRef]

125. Liu, J.Y.; Liao, T.L.; Huang, W.C.; Liu, Y.M.; Wu, K.M.; Lauderdale, T.L.; Tsai, S.F.; Kuo, S.C.; Kuo, H.C. Increased mcr-1 in Escherichia coli Isolates Co-Expressing ESBL and Mcr-1 Resistance Mechanisms from Different Origins in China. *Front. Microbiol.* **2019**, *10*, 49. [CrossRef]

126. Zhang, X.; Zhang, B.; Guo, Y.; Wang, J.; Zhao, P.; Liu, J.; He, K. Colistin Resistance Prevalence in Escherichia coli from Domestic Animals in Intensive Breeding Farms of Jiangsu Province. *Int. J. Food Microbiol.* **2019**, *291*, 87–90. [CrossRef]

127. Liu, B.T.; Song, F.J.; Zhou, M. Characterization of Highly Prevalent Plasmids Coharboring Mcr-1, OqxAB, and BlaCTX-M in Escherichia coli Isolates from Food-Producing Animals in China. *Microb. Drug Resist.* **2019**, *25*, 108–119. [CrossRef]

128. Yamaguchi, T.; Kawahara, R.; Harada, K.; Teruya, S.; Nakayama, T.; Motooka, D.; Nakamura, S.; Do Nguyen, P.; Kumeda, Y.; Van Dang, C.; et al. The Presence of Colistin Resistance Gene Mcr-1 and -3 in ESBL Producing Escherichia coli Isolated from Food in Ho Chi Minh City, Vietnam. *FEMS Microbiol. Lett.* **2018**, *365*, fny100. [CrossRef]

129. Yassin, A.K.; Zhang, J.; Wang, J.; Chen, L.; Kelly, P.; Butaye, P.; Lu, G.; Gong, J.; Li, M.; Wei, L.; et al. Identification and Characterization of Mcr Mediated Colistin Resistance in Extraintestinal Escherichia coli from Poultry and Livestock in China. *FEMS Microbiol. Lett.* **2017**, *364*, fnx242. [CrossRef]

130. Nishino, Y.; Shimojima, Y.; Suzuki, Y.; Ida, M.; Fukui, R.; Kuroda, S.; Hirai, A.; Sadamasu, K. Detection of Mcr-1 Gene Detected in Avian Poultry Production. *Pathogens* **2022**, *11*, 659. [CrossRef] [PubMed]
162. Mesa-Varona, O.; Kaspar, H.; Grobbel, M.; BA, T. Phenotypic Antimicrobial Resistance Data of Clinical and Non-Clinical Escherichia coli from Poultry in Germany between 2014 and 2017. *PLoS ONE* **2020**, *15*, e0243772. [CrossRef] [PubMed]

163. Pesciaroli, M.; CF, M.; Filippini, G.; EM, E.; Lovico, C.; Marchi, L.; Maresca, C.; Tenhagen, B.-A.; Orsini, S.; Scoccia, E.; et al. Antibiotic-Resistant Commensal Escherichia Coli Are Less Frequently Isolated from Poultry Raised Using Non-Conventional Management Systems than from Conventional Broiler. *Int. J. Food Microbiol.* **2020**, *314*, 108391. [CrossRef]

164. Kieffer, N.; Nordmann, P.; Moreno, A.M.; Moreno, I.Z.; Chaby, R.; Breton, A.; Tissières, P.; Poirel, L. Genetic and Functional Characterization of an MCR-3-like Enzyme-Producing Escherichia coli Isolate Recovered from Swine in Brazil. *Antimicrob. Agents Chemother.* **2018**, *62*, e00278-18. [CrossRef]

165. Meinersmann, R.J.; Ladely, S.R.; Plumbee, J.R.; Cook, K.L.; Thacker, E. Prevalence of Mcr-1 in the Cecal Contents of Food Animals in the United States. *Antimicrob. Agents Chemother.* **2017**, *61*, e02244-16. [CrossRef]

166. Delgado-Blas, J.F.; Ovejero, C.M.; Abadía-Parfito, L.; Gonzalez-Zorn, B. Coexistence of Mcr-1 and BlaNDM-1 in Escherichia coli from Venezuela. *Antimicrob. Agents Chemother.* **2016**, *60*, 6356–6358. [CrossRef]

167. Wang, Z.; Fu, Z.; Schwarz, S.; Yin, W.; Walsh, T.R.; Zhou, Y.; He, J.; Jiang, H.; Wang, Y.; Wang, S. Genetic Environment of Colistin Resistance Genes mcr-1 and mcr-3 in Escherichia coli from One Pig Farm in China. *Vet. Microbiol.* **2019**, *230*, 56–61. [CrossRef]

168. Dandachi, I.; Fayad, E.; El-Bazzal, B.; Daoud, Z.; Rolain, J.M. Prevalence of Extended-Spectrum Beta-Lactamase-Producing Gram-Negative Bacilli and Emergence of Mcr-1 Colistin Resistance Gene in Lebanese Swine Farms. *Microb. Drug Resist.* **2019**, *25*, 233–240. [CrossRef]

169. Li, J.; Hulth, A.; Nilsson, L.E.; Börjesson, S.; Chen, B.; Bi, Z.; Wang, Y.; Schwarz, S.; Wu, C. High Carriage Rate of Mcr-1 and Antimicrobial Resistance Genes mcr-1 and mcr-3 in Escherichia coli from One Pig Farm in China. *Diagn. Microbiol. Infect. Dis.* **2019**, *91*, 393–401. [CrossRef]

170. Tong, H.; Liu, J.; Yao, X.; Jia, H.; Wei, J.; Shao, D.; Liu, K.; Qiu, Y.; Ma, Z.; Li, B. High Carriage Rate of Mcr-1 and MCR-1 Resistant Escherichia coli Isolates from Swine Faecal Samples Collected from Eighteen Provinces in China. *Vet. Microbiol.* **2018**, *225*, 53–57. [CrossRef]

171. Wang, Z.; Fu, Z.; Schwarz, S.; Yin, W.; Walsh, T.R.; Zhou, Y.; He, J.; Jiang, H.; Wang, Y.; Wang, S. Genetic Environment of Colistin Resistance Genes mcr-1 and mcr-3 in Escherichia coli from One Pig Farm in China. *Vet. Microbiol.* **2019**, *230*, 56–61. [CrossRef]

172. Kong, L.H.; Lei, C.W.; Ma, S.Z.; Jiang, W.; Liu, B.H.; Wang, Y.X.; Guan, R.; Men, S.; Yuan, Q.W.; Cheng, G.Y.; et al. Various Sequence Types of Escherichia coli Isolates Coharboring BlaNDM-5 and Mcr-1 Genes from a Commercial Swine Farm in China. *Antimicrob. Agents Chemother.* **2017**, *61*, e02167-16. [CrossRef]

173. Li, R.; Xie, M.; Zhang, J.; Yang, Z.; Liu, L.; Liu, X.; Zheng, Z.; Chan, E.W.C.; Chen, S. Genetic Characterization of mcr-1-Bearing Plasmids to Depict Molecular Mechanisms Underlying Dissemination of the Colistin Resistance Determinant. *J. Antimicrob. Chemother.* **2017**, *72*, 393–401. [CrossRef]

174. Wang, Q.; Li, Z.; Lin, J.; Wang, X.; Deng, X.; Feng, Y. Complex Dissemination of the Diversified Mcr-1-Harbouring Plasmids in Escherichia coli of Different Sequence Types. *Oncotarget* **2016**, *7*, 82112–82122. [CrossRef] [PubMed]

175. Peng, Z.; Li, X.; Hu, Z.; Li, Z.; Lv, Y.; Lei, M.; Wu, B.; Chen, H.; Wang, X. Characteristics of Carbapenem-Resistant and Colistin-Resistant Escherichia coli Co-Producing NDm-1 and MCR-1 from Pig Farms in China. *Microorganisms* **2019**, *7*, 482. [CrossRef]

176. Do, K.H.; Parkhoo, H.E.; Byun, J.W.; Lee, W.K. Virulence and Antimicrobial Resistance Profiles of Escherichia coli Encoding Mcr Gene from Diarrhoeic Weaned Piglets in Korea during 2007–2016. *J. Glob. Antimicrob. Resist.* **2020**, *20*, 324–327. [CrossRef]

177. Shafiq, M.; Huang, J.; Ur Rahman, S.; Shah, J.M.; Chen, L.; Gao, Y.; Wang, L.; High Incidence of Multidrug-Resistant Escherichia coli Coharboring MBL and MBLCTX-M-15 Recovered from Pigs. *Infect. Drug Resist.* **2019**, *12*, 2135–2149. [CrossRef]

178. Fukuda, A.; Sato, T.; Shinagawa, M.; Takahashi, S.; Asai, T.; Yokota, S.I.; Usui, M.; Tamura, Y. High Prevalence of Mcr-1, Mcr-3 and Mcr-5 in Escherichia coli Derived from Diseased Pigs in Japan. *Int. J. Antimicrob. Agents* **2018**, *51*, 163–164. [CrossRef]

179. Lai, C.C.; Lin, Y.T.; Lin, Y.T.; Lu, M.C.; Shi, Z.Y.; Chen, Y.S.; Wang, L.S.; Tseng, S.H.; Lin, C.N.; Chen, Y.H.; et al. Clinical Characteristics of Patients with Bacteraemia Due to the Emergence of Mcr-1-Harbouring Enterobacteriaceae in Humans and Pigs in Taiwan. *Int. J. Antimicrob. Agents* **2018**, *52*, 651–657. [CrossRef]

180. Duggett, N.A.; Randall, L.P.; Horton, R.A.; Lemma, F.; Kirchner, M.; Nunez-Garcia, J.; Brena, C.; Williamson, S.M.; Teale, C.; Anjum, M.F. Molecular Epidemiology of Isolates with Multiple Mcr Plasmids from a Pig Farm in Great Britain: The Effects of Colistin Withdrawal in the Short and Long Term. *J. Antimicrob. Chemother.* **2018**, *73*, 3025–3033. [CrossRef]

181. Delannoy, S.; Le Devendec, L.; Jouy, E.; Fach, P.; Drider, D.; Kempf, I. Characterization of Colistin-Resistant Escherichia coli Isolated from Diseased Pigs in France. *Front. Microbiol.* **2017**, *8*, 2278. [CrossRef]

182. Kieffer, N.; Aires-de-Sousa, M.; Medronhina, P.; Poirel, L. High Rate of MCR-1—Producing Escherichia coli and Klebsiella Pneumoniae among Pigs, Portugal. *Emerg. Infect. Dis.* **2017**, *23*, 2023–2029. [CrossRef]

183. Hille, K.; Roschanski, N.; Rudden, I.; Woydt, J.; Hartmann, M.; Rösler, U.; Kreienbrock, L. Investigation of Potential Risk Factors for the Occurrence of Escherichia coli Isolates from German Fattening Pig Farms Harbouring the Mcr-1 Colistin—Resistance Gene. *Int. J. Antimicrob. Agents* **2018**, *51*, 177–180. [CrossRef]

184. Curcio, L.; Luppi, A.; Bonlauri, P.; Gherpelli, Y.; Pezzotti, G.; Pesciaroli, M.; Magistrali, C.F. Detection of the Colistin Resistance Gene MCR-1 in Pathogenic Escherichia coli from Pigs Affected by Post-Weaning Diarrhoea in Italy. *J. Glob. Antimicrob. Resist.* **2017**, *10*, 80–83. [CrossRef] [PubMed]
185. Roschanski, N.; Falgenhauer, L.; Grobmel, M.; Guenther, S.; Kreienbrock, L.; Imirzalioglu, C.; Roesler, U. Retrospective Survey of Mcr-1 and Mcr-2 in German Pig-Fattening Farms, 2011–2012. *Int. J. Antimicrob. Agents* 2017, 50, 266–271. [CrossRef]

186. Duggett, N.A.; Sayers, E.; AbuOun, M.; Ellis, R.J.; Nunez-Garcia, J.; Randall, L.; Horton, R.; Rogers, J.; Martelli, F.; Smith, R.P.; et al. Occurrence and Characterization of Mcr-1-Harbouring Escherichia Coli Isolated from Pigs in Great Britain from 2013 to 2015. *J. Antimicrob. Chemother.* 2017, 72, 691–695. [CrossRef]

187. El Garch, F.; Sauget, M.; Hoçquet, D.; Le Chaudee, D.; Woehrle, F.; Bertrand, X. Mcr-1 Is Borne by Highly Diverse Escherichia Coli Isolates since 2004 in Food-Producing Animals in Europe. *Clin. Microbiol. Infect.* 2017, 23, e1–e5. [CrossRef]

188. Bai, L.; Hurley, D.; Li, J.; Meng, Q.; Wang, J.; Fanning, S.; Xiong, Y. Characterisation of Multidrug-Resistant Shiga Toxin-Producing Escherichia Coli Cultured from Pigs in China: Co-Occurrence of Extended-Spectrum β-Lactamase- and Mcr-1-Encoding Genes on Plasmids. *Int. J. Antimicrob. Agents* 2016, 48, 445–448. [CrossRef]

189. Chabou, S.; Leulmi, H.; Rolain, J.M. Emergence of Mcr-1-Mediated Colistin Resistance in Escherichia Coli Isolates from Poultry in Algeria. *J. Glob. Antimicrob. Resist.* 2019, 16, 115–116. [CrossRef] [PubMed]

190. García-Meniño, I.; Díaz-Jiménez, D.; García, V.; de Toro, M.; Flamant-Simon, S.C.; Blanco, J.; Mora, A. Genomic Characterization of Prevalent Mcr-1, Mcr-4, and Mcr-5 Escherichia Coli within Swine Enteric Colibacillosis in Spain. *Front. Microbiol.* 2019, 10, 2469. [CrossRef]

191. Fournier, C.; Aires-de-Sousa, M.; Nordmann, P.; Poirel, L. Occurrence of CTX-M-15- and MCR-1-Producing Enterobacterales in Swine Enteric Colibacillosis in Spain. *Antimicrob. Agents Chemother.* 2019, 63, e02241-18. [CrossRef] [PubMed]

192. Kieffer, N.; Nordmann, P.; Millemann, Y.; Poirel, L. Functional Characterization of a Miniature Inverted Transposable Element at the Origin of Mcr-5 Gene Acquisition in Escherichia Coli. *Antimicrob. Agents Chemother.* 2019, 63, e00559-19. [CrossRef] [PubMed]

193. Magistrali, C.F.; Curcio, L.; Luppi, A.; Pezzotti, G.; Orsini, S.; Tofani, S.; Feudi, C.; Carattoli, A.; Villa, L. Mobile Colistin Resistance Genes in Escherichia Coli from Pigs Affected by Colibacillosis. *Int. J. Antimicrob. Agents* 2018, 52, 744–746. [CrossRef]

194. Ström Hallenberg, G.; Börjesson, S.; Sokerya, S.; Sothyra, T.; Magnusson, U. Detection of Mcr-Mediated Colistin Resistance in Escherichia Coli Isolates from Pigs in Small-Scale Farms in Cambodia. *Antimicrob. Agents Chemother.* 2019, 63, e00238-19. [CrossRef] [PubMed]

195. Büdel, T.; Kuenzli, E.; Claudio, L.; Zanella, R.; Bernasconi, O.J.; Fehr, J.; Mohammed, A.H.; Hassan, N.K.; Zinsstag, J.; Hatz, C.; Endimiani, A. Polycolonal Gut Colonization with Extended-Spectrum Cephalosporin- and/or Colistin-Resistant Enterobacteriaceae: A Normal Status for Hotel Employees on the Island of Zanzibar, Tanzania. *J. Antimicrob. Chemother.* 2019, 74, 2880–2890. [CrossRef] [PubMed]

196. Aworh, M.K.; Kwaga, J.K.P.; Hendriksen, R.S.; Okolocha, E.C.; Thakur, S. Genetic Relatedness of Multidrug Resistant Escherichia Coli Isolated from Humans, Chickens and Poultry Environments. *Antimicrob. Resist. Infect. Control.* 2021, 10, 58. [CrossRef]

197. Giani, T.; Sennati, S.; Antonelli, A.; Di Pilato, V.; Di Maggio, T.; Mantella, A.; Niccolai, C.; Spinici, M.; Monasterio, J.; Castellanos, P.; et al. High Prevalence of Carriage of Mcr-1-Positive Enteric Bacteria among Healthy Children from Rural Communities in the Chaco Region, Bolivia, September to October 2016. *Eurosurveillance* 2018, 23, 1800115. [CrossRef]

198. Berglund, B.; Chen, B.; Tärnberg, M.; Sun, Q.; Xu, L.; Welander, J.; Li, Y.; Bi, Z.; Nilsson, M.; Nilsson, L.E. Characterization of Extended-Spectrum β-Lactamase-Producing Escherichia Coli Harboring Mcr-1 and Toxin Genes from Human Fecal Samples from China. *Future Microbiol.* 2018, 13, 1647–1655. [CrossRef] [PubMed]

199. Yamamoto, Y.; Kawahara, R.; Fujiiya, Y.; Sasaki, T.; Hirai, I.; Khong, D.T.; Nguyen, T.N.; Nguyen, B.X. Wide Dissemination of Colistin-Resistant Escherichia Coli with the Mobile Resistance Gene Mcr in Healthy Residents in Vietnam. *J. Antimicrob. Chemother.* 2019, 74, 523–524. [CrossRef]

200. Bi, Z.; Berglund, B.; Sun, Q.; Nilsson, M.; Chen, B.; Tärnberg, M.; Ding, L.; Stålsby Lundborg, C.; Bi, Z.; Tomson, G.; et al. Prevalence of the Mcr-1 Colistin Resistance Gene in Extended-Spectrum β-Lactamase-Producing Escherichia Coli from Human Faecal Samples Collected in 2012 in Rural Villages in Shandong Province, China. *Int. J. Antimicrob. Agents* 2017, 49, 493–497. [CrossRef]

201. Kawahara, R.; Khong, D.T.; Le, H.V.; Phan, Q.N.; Nguyen, T.N.; Yamaguchi, T.; Kumed, Y.; Yamamoto, Y. Prevalence of Mcr-1 among Cefotaxime-Resistant Commensal Escherichia Coli in Residents of Vietnam. *Infect. Drug Resist.* 2019, 12, 3317–3325. [CrossRef]

202. Johura, F.T.; Tasnim, J.; Barman, I.; Biswas, S.R.; Jubyda, F.T.; Sultana, M.; George, C.M.; Camilli, A.; Seed, K.D.; Ahmed, N.; et al. Colistin-Resistant Escherichia Coli Carrying Mcr-1 In Food, Water, Hand Rinse, and Healthy Human Gut in Bangladesh. *Gut Pathog.* 2020, 12, 5. [CrossRef]

203. Fukuda, A.; Nakamura, H.; Umeda, K.; Yamamoto, K.; Hirai, Y.; Usui, M.; Ogasawara, J. Seven-Year Surveillance of the Prevalence of Antimicrobial-Resistant Escherichia Coli Isolates, with a Focus on ST131 Clones, among Healthy People in Osaka, Japan. *Int. J. Antimicrob. Agents* 2021, 57, 106298. [CrossRef]

204. Del Bianco, F.; Morotti, M.; Pedna, M.F.; Farabegoli, P.; Sambri, V. Microbiological Surveillance of Plasmid Mediated Collistin Resistance in Human Enterobacteriaceae Isolates in Romagna (Northern Italy): August 2016–July 2017. *Int. J. Infect. Dis.* 2018, 69, 96–98. [CrossRef] [PubMed]

205. Leangparkchart, T.; Gautret, P.; Brouqui, P.; Mimish, Z.; Raoult, D.; Rolain, J.M. Acquisition of Mcr-1 Plasmid-Mediated Collistin Resistance in Escherichia Coli and Klebsiella Pneumoniae during Hajj 2013 and 2014. *Antimicrob. Agents Chemother.* 2016, 60, 6998–6999. [CrossRef] [PubMed]
206. Vading, M.; Kabir, M.H.; Kalin, M.; Iversen, A.; Wiklund, S.; Naucler, P.; Giske, C.G. Frequent Acquisition of Low-Virulence Strains of ESBL-Producing Escherichia Coli in Travellers. J. Antimicrob. Chemother. 2016, 71, 3548–3555. [CrossRef]

207. Hasman, H.; Hammenrum, A.M.; Hansen, F.; Hendriksen, R.S.; Olesen, B.; Agero, Y.; Zankari, E.; Leekitcharoenphon, P.; Stegger, M.; Kaas, R.S.; et al. Detection of Mcr-1 Encoding Plasmid-Mediated Colistin-Resistant Escherichia Coli Isolates from Human Bloodstream Infection and Imported Chicken Meat, Denmark 2015. Eurosurveillance 2015, 20, 30085. [CrossRef] [PubMed]

208. Zogg, A.L.; Zarflhuk, K.; Nüesch-Inderbinen, M.; Stephan, R. Characteristics of ESBL-Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus Aureus (MRSA) Isolated from Swiss and Imported Raw Poutry Meatal Collected at Retail Level. Schweiz. Arch. Tierheilkd. 2016, 158, 451–456. [CrossRef]

209. Stoesser, N.; Mathers, A.J.; Moore, C.E.; Day, N.P.J.; Crook, D.W. Colistin Resistance Gene Mcr-1 and PHNSHP45 Plasmid in Human Isolates of Escherichia Coli and Klebsiella Pneumoniae. Lancet Infect. Dis. 2016, 16, 285–286. [CrossRef]

210. Coetzee, J.; Corcoran, C.; Prentice, E.; Moodley, M.; Mendelson, M.; Poirel, L.; Nordmann, P.; Brink, A.J. A Global Call for Action to Combat Antimicrobial Resistance: Can We Get It Right This Time? South Afr. Med. J. 2014, 104, 478–479. [CrossRef]

211. Walkty, A.; Karlowsky, J.A.; Adam, H.J.; Lagace-Wiens, P.; Baxter, M.; Mulvey, M.R.; McCracken, M.; Poutanen, S.M.; Roscoe, D.; Hasman, H.; Hammerum, A.M.; Hansen, F.; Hendriksen, R.S.; Olesen, B.; Agersø, Y.; Zankari, E.; Leekitcharoenphon, P.; Stegger, M.; Wang, Q.; Sun, J.; Ding, Y.; Li, X.P.; Liu, Y.H.; Feng, Y. Genomic Insights into Mcr-1-Positive Plasmids Carried by Colistin-Resistant Human Isolates of Escherichia Coli and Klebsiella Pneumoniae. Lancet Genet. Evol. 2018, 6, e555–e562. [CrossRef] [PubMed]

212. Faccone, D.; Rapoport, M.; Albornoz, E.; Celaya, F.; De Mendieta, J.; De Belder, D.; Lucero, C.; Gomez, S.; Danze, D.; Pasteran, F.; et al. Plasmidic Resistance to Colistin Mediated by Mcr-1 Gene in Escherichia Coli Clinical Isolates from Argentina: A Retrospective Study, 2012-2018. Pan Am. J. Public Health 2020, 44, e65. [CrossRef] [PubMed]

213. Ling, Y.; Wu, Z.; Wang, Y.; Tian, G.B.; Zhang, R.; Shen, Y.; Tyrrell, J.M.; Huang, X.; Zhou, H.; Lei, L.; Li, H.Y.; et al. Prevalence, Risk Factors, Outcomes, and Molecular Epidemiology of Mcr-1-Positive Enterobacteriaceae in Patients and Healthy Adults from China: An Multicentre Study. Lancet Infect. Dis. 2018, 18, 1157–1161. [CrossRef]

214. Feng, S.; Shen, C.; Chen, H.; Zheng, X.; Xia, Y.; Zhong, L.L.; Huang, X.; Wu, X.; Tian, G.B. Co-Production of MCR-1 and NDM-5 in Escherichia Coli Isolated from a Colonization Case of Inpatient. Infect. Drug Resist. 2017, 11, 355–356. [CrossRef]

215. Yoon, E.J.; Hong, J.S.; Yang, J.W.; Lee, K.J.; Lee, H.; Jeong, S.H. Detection of mcr-1 Plasmids in Enterobacteriaceae Isolates from Human Specimens: Comparison with Those in Escherichia Coli Isolates from Livestock in Korea. Ann. Lab. Med. 2018, 38, 555–562. [CrossRef]

216. Lu, H.; Wang, C.; Dong, G.; Xu, C.; Zhang, X.; Liu, H.; Zhang, M.; Cao, J.; Zhou, T. Prevalence and Molecular Characterization of Escherichia Coli Clinical Isolates Carrying Mcr-1 in a Chinese Teaching Hospital from 2013 to 2016. Front. Microbiol. 2018, 9, 2514. [CrossRef]

217. Shen, Y.; Wu, Z.; Wang, Y.; Zhang, R.; Zhou, H.; Wang, S.; Lei, L.; Li, M.; Cai, J.; Tyrrell, J.; et al. Heterogeneous and Flexible Transmission of Mcr-1 in Hospital-Associated Escherichia Coli. mBio 2018, 9, e00943-18. [CrossRef]

218. Eiamphungporn, P.; Yainoy, S.; Jumerd, C.; Tanarsuwongkul, R.; Tiengrim, S.; Thamilikutikul, V. Prevalence of the Colistin Resistance Gene Mcr-1 in Colistin-Resistant Enterobacteriaceae and Klebsiella Pneumoniae Isolated from Humans in Thailand. J. Glob. Antimicrob. Resist. 2018, 15, 32–35. [CrossRef] [PubMed]

219. Zhong, L.L.; Panh, H.; Shen, C.; Vitha, K.D.; Sheppard, A.E.; Huang, X.; Zeng, K.J.; Li, H.Y.; Zhang, X.F.; Patil, S.; et al. High Rates of Human Fecal Carriage of MCR-1-Positive Multi-Drug Resistant Enterobacteriaceae Isolates Emerge in China in Association with Successful Plasmid Families. Clin. Infect. Dis. 2018, 66, 676–685. [CrossRef]

220. Manohar, P.; Shanthini, T.; Ayyanan, R.; Bozdogan, B.; Wilson, A.; Tamhankar, A.J.; Nachimuthu, R.; Lopes, B.S. The Distribution of Carbapenem- and Colistin-Resistant Gram-Negative Bacteria from the Tamil Nadu Region in India. J. Med. Microbiol. 2017, 66, 874–883. [CrossRef]

221. Wang, Q.; Sun, J.; Ding, Y.; Li, X.P.; Liu, Y.H.; Feng, Y. Genomic Insights into Mcr-1-Positive Plasmids Carried by Colistin-Resistant Escherichia Coli Isolates from Patients. Antimicrob. Agents Chemother. 2017, 61, e00361-17. [CrossRef] [PubMed]

222. Wang, Y.; Tian, G.B.; Zhang, R.; Shen, Y.; Tyrrell, J.M.; Huang, X.; Zhou, H.; Lei, L.; Li, H.Y.; Dui, Y.; et al. Prevalence, Risk Factors, Outcomes, and Molecular Epidemiology of MCR-1-Positive Enterobacteriaceae in Patients and Healthy Adults from China: An Epidemiological and Clinical Study. Lancet Infect. Dis. 2017, 17, 390–399. [CrossRef]

223. Quan, J.; Li, X.; Chen, Y.; Jiang, Y.; Zhou, Z.; Zhang, H.; Sun, L.; Ruan, Z.; Feng, Y.; Akova, M.; et al. Prevalence of MCR-1 in Escherichia Coli and Klebsiella Pneumoniae Recovered from Bloodstream Infections in China: A Multicentre Longitudinal Study. Lancet Infect. Dis. 2017, 17, 400–410. [CrossRef]

224. Kim, Y.A.; Yong, D.; Jeong, S.H.; Lee, K. Colistin Resistance in Escherichia Coli Isolates from Patients with Bloodstream Infection in Korea. Ann. Lab. Med. 2017, 37, 172–173. [CrossRef] [PubMed]

225. Yu, H.; Qu, F.; Shan, B.; Huang, B.; Jia, W.; Chen, C.; Li, A.; Miao, M.; Zhang, X.; Bao, C.; et al. Detection of the Mcr-1 Colistin Resistance Gene in Carbapenem-Resistant Enterobacteriaceae from Different Hospitals in China. Antimicrob. Agents Chemother. 2016, 60, 5033–5035. [CrossRef]

226. Zhong, Y.M.; Liu, W.E.; Zheng, Z.F. Epidemiology and Molecular Characterization of Mcr-1 in Escherichia Coli Recovered from Patients with Bloodstream Infections in Changsha, Central China. Infect. Drug Resist. 2019, 12, 2069–2076. [CrossRef] [PubMed]

227. Lee, Y.L.; Lu, M.C.; Shao, P.L.; Lu, P.L.; Chen, Y.H.; Cheng, S.H.; Ko, W.C.; Lin, C.Y.; Wu, T.S.; Yen, M.Y.; et al. Nationwide Surveillance of Antimicrobial Resistance among Clinically Important Gram-Negative Bacteria, with an Emphasis on Carbapenems
251. San, N.; Aung, M.S.; Thu, P.P.; Myint, Y.Y.; Aung, M.T.; San, T.; Mar, T.T.; Lwin, M.M.; Maw, W.W.; Hlaing, M.S.; et al. First Detection of the Mcr-1 Colistin Resistance Gene in Escherichia Coli from a Patient with Urinary Tract Infection in Myanmar. New Microbes New Infect. 2019, 30, 100550. [CrossRef] [PubMed]

252. Henig, O.; Rojas, L.J.; Bachman, M.A.; Rudin, S.D.; Brennan, B.M.; Soehnlen, M.K.; Jones, K.L.; Mills, J.P.; Dombecki, C.R.; Valyko, A.M.; et al. Identification of Four Patients with Colistin-Resistant Escherichia Coli Containing the Mobile Colistin Resistance Mcr-1 Gene from a Single Health System in Michigan. Infect. Control. Hosp. Epidemiol. 2019, 40, 1059–1062. [CrossRef]

253. Chan, W.S.; Au, C.H.; Ho, D.N.; Chan, T.L.; Ma, E.S.K.; Tang, B.S.F. Prospective Study on Human Fecal Carriage of Enterobacteriaceae Possessing Mcr-1 and Mcr-2 Genes in a Regional Hospital in Hong Kong. BMC Infect. Dis. 2018, 18, 1. [CrossRef]

254. Li, Y.; Sun, Q.L.; Shen, Y.; Zhang, Y.; Yang, J.W.; Bin Shu, L.; Zhou, H.W.; Wang, Y.; Wang, B.; Zhang, R.; et al. Rapid Increase in Prevalence of Carbapenem-Resistant Enterobacteriaceae (CRE) and Emergence of Colistin Resistance Gene Mcr-1 in CRE in a Hospital in Henan, China. J. Clin. Microbiol. 2018, 56, 81. [CrossRef] [PubMed]

255. Luo, Q.; Yu, W.; Zhou, K.; Guo, L.; Shen, P.; Lu, H.; Huang, C.; Xu, H.; Xu, S.; Xiao, Y.; et al. Molecular Epidemiology and Colistin Resistant Mechanism of Mcr-Positive and Mcr-Negative Clinical Isolated Escherichia Coli. Front. Microbiol. 2017, 8, 2262. [CrossRef]

256. He, Q.-W.; Xu, X.-H.; Lan, F.-J.; Zhao, Z.-C.; Wu, Z.-Y.; Cao, Y.-P.; Li, B. Molecular Characteristic of Mcr-1 Producing Escherichia Coli in a Chinese University Hospital. Ann. Clin. Microbiol. Antimicrob. 2017, 16, 32. [CrossRef]

257. Nijhuis, R.H.T.; Veldman, K.T.; Schelfaut, J.; Van Essen-Zandbergen, A.; Wessels, E.; Claas, E.C.J.; Gooskens, J. Detection of the Plasmid-Mediated Colistin-Resistance Gene MCR-1 in Clinical Isolates and Stool Specimens Obtained from Hospitalized Patients Using a Newly Developed Real-Time PCR Assay. J. Antimicrob. Chemother. 2016, 71, 2344–2346. [CrossRef] [PubMed]

258. Principe, L.; Piazza, A.; Mauri, C.; Anesi, A.; Bracco, S.; Brigante, G.; Casari, E.; Agrappi, C.; Caltagirone, M.; Novazzi, F.; et al. Multicenter Prospective Study on the Prevalence of Colistin Resistance in Escherichia Coli: Relevance of Mcr-1-Positive Clinical Isolates in Lombardy, Northern Italy. Infect. Drug Resist. 2018, 11, 377–385. [CrossRef]

259. Newton-Foot, M.; Snyman, Y.; Maloba, M.R.B.; Whitelaw, A.C. Plasmid-Mediated MCR-1 Colistin Resistance in Escherichia coli and Klebsiella Spp. Clinical Isolates from the Western Cape Region of South Africa. Antimicrob. Resist. Infect. Control. 2017, 6, 78. [CrossRef]

260. Sagoo, G.S.; Little, J.; Higgins, J.P.T. Systematic Reviews of Genetic Association Studies. PLoS Med. 2009, 6, e1000028. [CrossRef]

261. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Grp, P. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (Reprinted from Annals of Internal Medicine). Phys. Ther. 2009, 89, 873–880. [CrossRef] [PubMed]